Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

RX 0301

Next Previous
Drug Profile

RX 0301

Alternative Names: HC-0301; RX-0301; WGI-0301

Latest Information Update: 05 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Rexahn Pharmaceuticals
  • Developer Rexahn Pharmaceuticals; Zhejiang Haichang Biotechnology
  • Class Antineoplastics; Antisense oligonucleotides
  • Mechanism of Action Proto-oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Liver cancer
  • Phase I Solid tumours
  • Discontinued Ovarian cancer; Pancreatic cancer; Renal cell carcinoma

Most Recent Events

  • 20 Apr 2026 Zhejiang Haichang Biotech plans a phase II trial for Liver cancer (Second line therapy or greater, Combination therapy, Late-stage disease) in September 2026 (NCT07540832)
  • 27 Mar 2026 Zhejiang Haichang Biotech plans a phase II trial for Liver cancer and Renal cell carcinoma (Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV), in June 2026 (NCT07494435)
  • 18 Sep 2025 RX 0301 is still in phase-I clinical trials in Solid tumours(Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) in USA (IV) (NCT05267899)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top